Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation
NCT07918937· First Hospital of China Medical University· Source
Contact: Yaning Chen (principal investigator)
Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xue Chen, Doctor
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Hong Peng, Doctor
Recruiting
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
NCT07892755· Guizhou Provincial People's Hospital· Source
Contact: Yong Li, MD
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961· Phase 3· Nanjing Minova Pharmaceutical Co., Ltd.· Source
Contact: Hui Xiang
Active, not recruiting
ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy
NCT07681414· Guizhou Provincial People's Hospital· Source
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xianwei Ye, Doctor
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: DEYI ZHENG, Doctor
Recruiting
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT07402239· United Innomed(Shanghai) Limited· Source
Contact: WU Qiang
Not yet recruiting
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
NCT07425210· Phase 2· Haisco Pharmaceutical Group Co., Ltd.· Source
Contact: Daishun Liu, M.D.
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600· Hoffmann-La Roche· Source
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Yan Zha
Active, not recruiting
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407· AstraZeneca· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Hong Peng (principal investigator)
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xianwei Ye, Doctor
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345· Chinese Academy of Sciences· Source
Contact: Rongpin Wang
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Yong Li, Doctor
Not yet recruiting
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041· Beijing Friendship Hospital· Source
Contact: Hong Peng (principal investigator)
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Yu Zhang, M.D.
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Jun Liu
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338· Phase 2· Suzhou Sanegene Bio Inc.· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Contact: US Biogen Clinical Trial Center
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265· Phase 3· Beletalent (Zhuhai) Pharmaceutical Co., Ltd· Source
Contact: Hongpei Ji
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Xianwei Ye, Doctor
Not yet recruiting
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011· Yan Zhang· Source
Contact: Xiao Hu
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Yong Li
Not yet recruiting
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274· Guangdong Association of Clinical Trials· Source
Contact: Chuan Xu, MD
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Lin Liu, MD
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840· Jinling Hospital, China· Source
Contact: Wang
Active, not recruiting
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069· Phase 3· Hutchmed· Source
Contact: Xiangpeng Guo
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yu Zhang, Doctor
Recruiting
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
NCT06121505· Phase 2· Sichuan University· Source
Contact: Yu Zhang
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Contact: Yong Li
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· Phase 3· Gilead Sciences· Source
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Jun Liu, Doctor
Not yet recruiting
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892· Phase 3· Suzhou Puhe Pharmaceutical Technology Co., LTD· Source
Contact: Xianwei Ye
Active, not recruiting
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287· Phase 3· RemeGen Co., Ltd.· Source
Recruiting
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
NCT05590871· Shanghai Hongdian Medical CO., LTD· Source
Contact: Yuehui Yin, MD
Active, not recruiting
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825· Phase 2· Sichuan University· Source
Active, not recruiting
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894· Phase 3· Taizhou Hanzhong biomedical co. LTD· Source
Showing 50 of 57.